More on PRME
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.95 |
|
|||
| Open | $2.95 | ||||
| 52 Wk High | $21.72 | ||||
| 52 Wk Low | $18.36 | ||||
| Day High | $2.95 | ||||
| Day Low | $2.95 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,853 | ||||
- Prime Medicine gets FDA clearance for Wilson disease gene therapy trial
- Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
- H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)
- TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'
- BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff
- Form 8-K Prime Medicine, Inc. For: Jul 06
- Prime Medicine wins arbitration against Beam Therapeutics over PM647
- Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
- H.C. Wainwright Upgrades Prime Medicine (PRME) to Buy
- FDA grants RMAT designation to Prime Medicine's CGD therapy PM359
Entities mentioned with PRME
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- IPO | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- Earnings | View Related Stories »
- Show More...
